Adsilico has developed a method for trialling new devices before entering human clinical tests that the company claims reduces costs, accelerates R&D timelines and eliminates the need for animal testing.
Adsilico has raised €4.1M across 1 funding round from 2 investors, most recently a round in Feb 2024. Based in Leeds, UK; active in Healthtech. Data as of 7 Aug 2026.
Timing: overdue vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2024-02-26 | Other | €4.1M |
| Northern Gritstone,Parkwalk Advisors |
| View deal → |
